quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:27:00·10d
PRRelease
Cardiol Therapeutics Inc. logo

Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart

CRDL· Cardiol Therapeutics Inc.
Health Care
Original source

Companies

  • CRDL
    Cardiol Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Jun 2UpdateH.C. Wainwright$9.00
  • Jan 28UpdateRodman & Renshaw$7.00
  • Jun 26UpdateROTH MKM$10.00
  • Apr 22UpdateH.C. Wainwright$9.00
  • Dec 17UpdateCantor Fitzgerald$8.00
  • Dec 3UpdateCanaccord Genuity$8.00

Related

  • SEC10d
    SEC Form 6-K filed by Cardiol Therapeutics Inc.
  • SEC13d
    SEC Form 6-K filed by Cardiol Therapeutics Inc.
  • SEC23d
    SEC Form 6-K filed by Cardiol Therapeutics Inc.
  • PR23d
    Cardiol Therapeutics Announces Year-End 2025 Update on Operations
  • SEC23d
    SEC Form 40-F filed by Cardiol Therapeutics Inc.
  • SEC57d
    SEC Form 6-K filed by Cardiol Therapeutics Inc.
  • PR57d
    Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference
  • SEC72d
    SEC Form 6-K filed by Cardiol Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022